Equity Update: Stocks Push Higher Despite Virus Concerns Equity Update: Stocks Push Higher Despite Virus Concerns Equity Update: Stocks Push Higher Despite Virus Concerns

Equity Update: Stocks Push Higher Despite Virus Concerns

Equities 8 minutes to read

Summary:  Today we take a look at the latest moves across global markets and check in some company updates relating to the virus outbreak.

US markets stumbled on Thursday, taking a breather from the run of fresh highs over prior sessions. News of a spike in COVID-19 cases from China’s Hubei province post revising its diagnosis methods initially saw equity indices falter, but investors nerves were soothed after the WHO said a spike in China’s coronavirus diagnoses didn’t necessarily reflect a sudden surge in the epidemic. 

Later in the session, news that the FED will dial back their overnight repo operations starting today pushed US stocks into the red, posting their first decline this week.

Heading into the European session stocks are mixed in Asia – some indices have maintained the dampened sentiment from Wall Street and others have pushed higher. Australian equities are pushing higher, despite an indecisive start to trade. The banks, index heavyweights, are driving upwards momentum as Commonwealth Bank (CBA) pushed to a 5 year high, trading above $90. This after reporting a resilient trading update earlier in the week, along with NAB – more on those updates here. In the current environment, where rates are set to stay low and there is ample liquidity in markets investors are focusing on the worst being over, taking all the good news they can get and running with it.

Virus Outbreak

New cases in Hubei have jumped as diagnosis method changes - A detailed analysis of what this step means should be left for the medical professionals and epidemiologists, but as we noted yesterday one thing is for sure, there is a huge question mark over the reliability of all data relating to COVID-19 cases. This means that within any forecast outcomes should be embedded an enormous degree of variability. As is often case, garbage in, garbage out - incorrect or poor-quality input will produce faulty output which is likely the case here given the lack of reliable data.

The situation remains fluid, however equity markets still don’t appear to be overly worried whilst the outbreak is relatively contained within China. If we look to commodities and haven treasuries we see a different picture, where the scale of demand destruction is considered and caution is visible. Equity investors sentiment is complacent given China’s contribution to global growth and importance within intertwined global supply chains generating the potential for production bottlenecks – particularly in tech and autos sectors, notwithstanding lost output as it relates to goods and services trade. Forecasting that is dependent upon the 2003 SARs outbreak is likely not a good replica – China is a far larger component of the global economy than in 2003, and consumer spending also makes up a bigger share of China's economy.

Shutdowns in China look to be more protracted than original expectations, many factories have not resumed production and cities are still on lockdown as measures are taken to limit the virus spread. This is particularly concerning not just in terms of the direct effects but also the capacity for non-linear secondary effects to cascade as shutdowns become more protracted, this is not priced into equities. However, upside momentum is strong, particularly for US equity indices, and investors are heeding the impending monetary and fiscal stimulus and influx of liquidity from China. 2019 has already proved how costly it is to fight liquidity, and investors are heeding the central bank put, as globally a raft of policymakers have already exhibited by word and deed their willingness to intervene and lend support. Given the complete lack of reliable data we must balance complacent markets with elevated tail risks, participating in the upside momentum and maintaining optionality with respect to potentially much more negative outcomes.

Fat-tails – Fat tail risk events are rare but bring with them the prospect of large negative returns. Tail risk events can occur at both ends of the spectrum, but it is the negative ones (left tail) we are concerned about.

Traditional methodologies of deriving asset pricing or market returns rely on a normal bell curve to make assumptions; typically, markets do not actually behave this way. Within a normal distribution, most variations fall within 3 standard deviations of the mean of the distribution. This then understates the magnitude of extreme risk and volatility events, as in reality markets have fatter tails. The current virus outbreak may represent an example of a devastating real world event for which a normally distributed model will understate various outcomes potentially leading to large mispricing of risk.

Luckily, many tools are available to protect portfolios and hedge against these tail risks. Diversification across multiple asset classes and geographies significantly reduces portfolio risk. Along with hedging strategies that use options or CFDs as a risk protection mechanism.

Current fallout – today’s update

Given the question marks over the reported case data, we look to examine the ongoing fallout as it relates to supply constraints, company earnings, trade data and travel/tourism.

Alibaba, a company who are probably one of the best bellwethers to give us an update on the true state of affairs on the ground in China, are concerned. On Thursday’s earnings call, Alibaba Group’s CFO Maggie Wu said overall revenue growth for 1Q would be negative, as the economic shock from the virus has already shut down two-thirds of the Chinese economy. The Group’s CEO Daniel Zhang also warned that the Covid-19 outbreak in China is developing into a “black swan event”.

Royal Caribbean Cruises earlier today slashed their earnings outlook and cancelled 18 cruise itineraries.

Mattel, the toy maker, said production would be delayed given their manufacturing workforce in China has been impacted. Mattel were expecting to resume factory production in the first week of February but have pushed that out to next week.

Fiat Chrysler will be halting their operations at a factory in Serbia due to lack of parts from China. This is a key read on how heavily intertwined global supply chains are being disrupted as the shutdowns in China trickle down production lines. Can the Eurozone’s languishing manufacturing sector afford to have nascent green shoots trampled by production bottlenecks? 

Passenger car sales in China have slumped by 22% YoY in January 2020 – the largest ever drop for the month of January. The lockdown of Wuhan, the Chinese city were the epicentre of the virus outbreak sits, is the primary reason for this weakness. This will also affect the German auto manufacturers for whom China is an important market. China accounts for about 40% of VW's global passenger vehicle sales, and about 30% at Daimler and BMW.

Other Activity Measures from China

Charts courtesy of Capital Economics

Source: Capital Economics - China Coal Consumption

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.